Illinois General Assembly - Full Text of SB2952
Illinois General Assembly

Previous General Assemblies

Full Text of SB2952  100th General Assembly


Sen. Melinda Bush

Filed: 5/3/2018





10000SB2952sam004LRB100 16820 RLC 39676 a


2    AMENDMENT NO. ______. Amend Senate Bill 2952, AS AMENDED,
3by replacing everything after the enacting clause with the
5    "Section 5. The Illinois Controlled Substances Act is
6amended by changing Sections 316, 318, and 320 as follows:
7    (720 ILCS 570/316)
8    Sec. 316. Prescription Monitoring Program.
9    (a) The Department must provide for a Prescription
10Monitoring Program for Schedule II, III, IV, and V controlled
11substances that includes the following components and
13        (1) The dispenser must transmit to the central
14    repository, in a form and manner specified by the
15    Department, the following information:
16            (A) The recipient's name and address.



10000SB2952sam004- 2 -LRB100 16820 RLC 39676 a

1            (B) The recipient's date of birth and gender.
2            (C) The national drug code number of the controlled
3        substance dispensed.
4            (D) The date the controlled substance is
5        dispensed.
6            (E) The quantity of the controlled substance
7        dispensed and days supply.
8            (F) The dispenser's United States Drug Enforcement
9        Administration registration number.
10            (G) The prescriber's United States Drug
11        Enforcement Administration registration number.
12            (H) The dates the controlled substance
13        prescription is filled.
14            (I) The payment type used to purchase the
15        controlled substance (i.e. Medicaid, cash, third party
16        insurance).
17            (J) The patient location code (i.e. home, nursing
18        home, outpatient, etc.) for the controlled substances
19        other than those filled at a retail pharmacy.
20            (K) Any additional information that may be
21        required by the department by administrative rule,
22        including but not limited to information required for
23        compliance with the criteria for electronic reporting
24        of the American Society for Automation and Pharmacy or
25        its successor.
26        (2) The information required to be transmitted under



10000SB2952sam004- 3 -LRB100 16820 RLC 39676 a

1    this Section must be transmitted not later than the end of
2    the next business day after the date on which a controlled
3    substance is dispensed, or at such other time as may be
4    required by the Department by administrative rule.
5        (3) A dispenser must transmit the information required
6    under this Section by:
7            (A) an electronic device compatible with the
8        receiving device of the central repository;
9            (B) a computer diskette;
10            (C) a magnetic tape; or
11            (D) a pharmacy universal claim form or Pharmacy
12        Inventory Control form;
13        (4) The Department may impose a civil fine of up to
14    $100 per day for willful failure to report controlled
15    substance dispensing to the Prescription Monitoring
16    Program. The fine shall be calculated on no more than the
17    number of days from the time the report was required to be
18    made until the time the problem was resolved, and shall be
19    payable to the Prescription Monitoring Program.
20    (b) The Department, by rule, may include in the
21Prescription Monitoring Program certain other select drugs
22that are not included in Schedule II, III, IV, or V. The
23Prescription Monitoring Program does not apply to controlled
24substance prescriptions as exempted under Section 313.
25    (c) The collection of data on select drugs and scheduled
26substances by the Prescription Monitoring Program may be used



10000SB2952sam004- 4 -LRB100 16820 RLC 39676 a

1as a tool for addressing oversight requirements of long-term
2care institutions as set forth by Public Act 96-1372. Long-term
3care pharmacies shall transmit patient medication profiles to
4the Prescription Monitoring Program monthly or more frequently
5as established by administrative rule.
6    (d) The Department of Human Services shall appoint a
7full-time Clinical Director of the Prescription Monitoring
9    (e) (Blank).
10    (f) Within one year of the effective date of this
11amendatory Act of the 100th General Assembly, the Department
12shall adopt rules requiring all Electronic Health Records
13Systems to interface with the Prescription Monitoring Program
14application program on or before January 1, 2021 to ensure that
15all providers have access to specific patient records during
16the treatment of their patients. These rules shall also address
17the electronic integration of pharmacy records with the
18Prescription Monitoring Program to allow for faster
19transmission of the information required under this Section.
20The Department shall establish actions to be taken if a
21prescriber's Electronic Health Records System does not
22effectively interface with the Prescription Monitoring Program
23within the required timeline.
24    (g) The Department, in consultation with the Advisory
25Committee, shall adopt rules allowing licensed prescribers or
26pharmacists who have registered to access the Prescription



10000SB2952sam004- 5 -LRB100 16820 RLC 39676 a

1Monitoring Program to authorize a licensed or non-licensed
2designee employed in that licensed prescriber's office or a
3licensed designee in a licensed pharmacist's pharmacy, and who
4has received training in the federal Health Insurance
5Portability and Accountability Act to consult the Prescription
6Monitoring Program on their behalf. The rules shall include
7reasonable parameters concerning a practitioner's authority to
8authorize a designee, and the eligibility of a person to be
9selected as a designee.
10(Source: P.A. 99-480, eff. 9-9-15; 100-564, eff. 1-1-18.)
11    (720 ILCS 570/318)
12    Sec. 318. Confidentiality of information.
13    (a) Information received by the central repository under
14Section 316 and former Section 321 is confidential.
15    (a-1) To ensure the federal Health Insurance Portability
16and Accountability Act privacy of an individual's prescription
17data reported to the Prescription Monitoring Program received
18from a retail dispenser under this Act, and in order to execute
19the duties and responsibilities under Section 316 of this Act
20and rules for disclosure under this Section, the Clinical
21Director of the Prescription Monitoring Program or his or her
22designee shall maintain direct access to all Prescription
23Monitoring Program data. Any request for Prescription
24Monitoring Program data from any other department or agency
25must be approved in writing by the Clinical Director of the



10000SB2952sam004- 6 -LRB100 16820 RLC 39676 a

1Prescription Monitoring Program or his or her designee unless
2otherwise permitted by law. Prescription Monitoring Program
3data shall only be disclosed as permitted by law.
4    (a-2) As an active step to address the current opioid
5crisis in this State and to prevent and reduce addiction
6resulting from a sports injury or an accident, the Prescription
7Monitoring Program and the Department of Public Health shall
8coordinate a continuous review of the Prescription Monitoring
9Program and the Department of Public Health data to determine
10if a patient may be at risk of opioid addiction. Each patient
11discharged from any medical facility with an International
12Classification of Disease, 10th edition code related to a sport
13or accident injury shall be subject to the data review. If the
14discharged patient is dispensed a controlled substance, the
15Prescription Monitoring Program shall alert the patient's
16prescriber as to the addiction risk and urge each to follow the
17Centers for Disease Control and Prevention guidelines or his or
18her respective profession's treatment guidelines related to
19the patient's injury. This subsection (a-2), other than this
20sentence, is inoperative on or after January 1, 2024.
21    (b) The Department must carry out a program to protect the
22confidentiality of the information described in subsection
23(a). The Department may disclose the information to another
24person only under subsection (c), (d), or (f) and may charge a
25fee not to exceed the actual cost of furnishing the



10000SB2952sam004- 7 -LRB100 16820 RLC 39676 a

1    (c) The Department may disclose confidential information
2described in subsection (a) to any person who is engaged in
3receiving, processing, or storing the information.
4    (d) The Department may release confidential information
5described in subsection (a) to the following persons:
6        (1) A governing body that licenses practitioners and is
7    engaged in an investigation, an adjudication, or a
8    prosecution of a violation under any State or federal law
9    that involves a controlled substance.
10        (2) An investigator for the Consumer Protection
11    Division of the office of the Attorney General, a
12    prosecuting attorney, the Attorney General, a deputy
13    Attorney General, or an investigator from the office of the
14    Attorney General, who is engaged in any of the following
15    activities involving controlled substances:
16            (A) an investigation;
17            (B) an adjudication; or
18            (C) a prosecution of a violation under any State or
19        federal law that involves a controlled substance.
20        (3) A law enforcement officer who is:
21            (A) authorized by the Illinois State Police or the
22        office of a county sheriff or State's Attorney or
23        municipal police department of Illinois to receive
24        information of the type requested for the purpose of
25        investigations involving controlled substances; or
26            (B) approved by the Department to receive



10000SB2952sam004- 8 -LRB100 16820 RLC 39676 a

1        information of the type requested for the purpose of
2        investigations involving controlled substances; and
3            (C) engaged in the investigation or prosecution of
4        a violation under any State or federal law that
5        involves a controlled substance.
6        (4) Select representatives of the Department of
7    Children and Family Services through the indirect online
8    request process. Access shall be established by an
9    intergovernmental agreement between the Department of
10    Children and Family Services and the Department of Human
11    Services.
12    (e) Before the Department releases confidential
13information under subsection (d), the applicant must
14demonstrate in writing to the Department that:
15        (1) the applicant has reason to believe that a
16    violation under any State or federal law that involves a
17    controlled substance has occurred; and
18        (2) the requested information is reasonably related to
19    the investigation, adjudication, or prosecution of the
20    violation described in subdivision (1).
21    (f) The Department may receive and release prescription
22record information under Section 316 and former Section 321 to:
23        (1) a governing body that licenses practitioners;
24        (2) an investigator for the Consumer Protection
25    Division of the office of the Attorney General, a
26    prosecuting attorney, the Attorney General, a deputy



10000SB2952sam004- 9 -LRB100 16820 RLC 39676 a

1    Attorney General, or an investigator from the office of the
2    Attorney General;
3        (3) any Illinois law enforcement officer who is:
4            (A) authorized to receive the type of information
5        released; and
6            (B) approved by the Department to receive the type
7        of information released; or
8        (4) prescription monitoring entities in other states
9    per the provisions outlined in subsection (g) and (h)
10    below;
11confidential prescription record information collected under
12Sections 316 and 321 (now repealed) that identifies vendors or
13practitioners, or both, who are prescribing or dispensing large
14quantities of Schedule II, III, IV, or V controlled substances
15outside the scope of their practice, pharmacy, or business, as
16determined by the Advisory Committee created by Section 320.
17    (g) The information described in subsection (f) may not be
18released until it has been reviewed by an employee of the
19Department who is licensed as a prescriber or a dispenser and
20until that employee has certified that further investigation is
21warranted. However, failure to comply with this subsection (g)
22does not invalidate the use of any evidence that is otherwise
23admissible in a proceeding described in subsection (h).
24    (h) An investigator or a law enforcement officer receiving
25confidential information under subsection (c), (d), or (f) may
26disclose the information to a law enforcement officer or an



10000SB2952sam004- 10 -LRB100 16820 RLC 39676 a

1attorney for the office of the Attorney General for use as
2evidence in the following:
3        (1) A proceeding under any State or federal law that
4    involves a controlled substance.
5        (2) A criminal proceeding or a proceeding in juvenile
6    court that involves a controlled substance.
7    (i) The Department may compile statistical reports from the
8information described in subsection (a). The reports must not
9include information that identifies, by name, license or
10address, any practitioner, dispenser, ultimate user, or other
11person administering a controlled substance.
12    (j) Based upon federal, initial and maintenance funding, a
13prescriber and dispenser inquiry system shall be developed to
14assist the health care community in its goal of effective
15clinical practice and to prevent patients from diverting or
16abusing medications.
17        (1) An inquirer shall have read-only access to a
18    stand-alone database which shall contain records for the
19    previous 12 months.
20        (2) Dispensers may, upon positive and secure
21    identification, make an inquiry on a patient or customer
22    solely for a medical purpose as delineated within the
23    federal HIPAA law.
24        (3) The Department shall provide a one-to-one secure
25    link and encrypted software necessary to establish the link
26    between an inquirer and the Department. Technical



10000SB2952sam004- 11 -LRB100 16820 RLC 39676 a

1    assistance shall also be provided.
2        (4) Written inquiries are acceptable but must include
3    the fee and the requestor's Drug Enforcement
4    Administration license number and submitted upon the
5    requestor's business stationery.
6        (5) As directed by the Prescription Monitoring Program
7    Advisory Committee and the Clinical Director for the
8    Prescription Monitoring Program, aggregate data that does
9    not indicate any prescriber, practitioner, dispenser, or
10    patient may be used for clinical studies.
11        (6) Tracking analysis shall be established and used per
12    administrative rule.
13        (7) Nothing in this Act or Illinois law shall be
14    construed to require a prescriber or dispenser to make use
15    of this inquiry system.
16        (8) If there is an adverse outcome because of a
17    prescriber or dispenser making an inquiry, which is
18    initiated in good faith, the prescriber or dispenser shall
19    be held harmless from any civil liability.
20    (k) The Department shall establish, by rule, the process by
21which to evaluate possible erroneous association of
22prescriptions to any licensed prescriber or end user of the
23Illinois Prescription Information Library (PIL).
24    (l) The Prescription Monitoring Program Advisory Committee
25is authorized to evaluate the need for and method of
26establishing a patient specific identifier.



10000SB2952sam004- 12 -LRB100 16820 RLC 39676 a

1    (m) Patients who identify prescriptions attributed to them
2that were not obtained by them shall be given access to their
3personal prescription history pursuant to the validation
4process as set forth by administrative rule.
5    (n) The Prescription Monitoring Program is authorized to
6develop operational push reports to entities with compatible
7electronic medical records. The process shall be covered within
8administrative rule established by the Department.
9    (o) Hospital emergency departments and freestanding
10healthcare facilities providing healthcare to walk-in patients
11may obtain, for the purpose of improving patient care, a unique
12identifier for each shift to utilize the PIL system.
13    (p) The Prescription Monitoring Program shall
14automatically create a log-in to the inquiry system when a
15prescriber or dispenser obtains or renews his or her controlled
16substance license. The Department of Financial and
17Professional Regulation must provide the Prescription
18Monitoring Program with electronic access to the license
19information of a prescriber or dispenser to facilitate the
20creation of this profile. The Prescription Monitoring Program
21shall send the prescriber or dispenser information regarding
22the inquiry system, including instructions on how to log into
23the system, instructions on how to use the system to promote
24effective clinical practice, and opportunities for continuing
25education for the prescribing of controlled substances. The
26Prescription Monitoring Program shall also send to all enrolled



10000SB2952sam004- 13 -LRB100 16820 RLC 39676 a

1prescribers, dispensers, and designees information regarding
2the unsolicited reports produced pursuant to Section 314.5 of
3this Act.
4    (q) A prescriber or dispenser may authorize a designee to
5consult the inquiry system established by the Department under
6this subsection on his or her behalf, provided that all the
7following conditions are met:
8        (1) the designee so authorized is employed by the same
9    hospital or health care system; is employed by the same
10    professional practice; or is under contract with such
11    practice, hospital, or health care system;
12        (2) the prescriber or dispenser takes reasonable steps
13    to ensure that such designee is sufficiently competent in
14    the use of the inquiry system;
15        (3) the prescriber or dispenser remains responsible
16    for ensuring that access to the inquiry system by the
17    designee is limited to authorized purposes and occurs in a
18    manner that protects the confidentiality of the
19    information obtained from the inquiry system, and remains
20    responsible for any breach of confidentiality; and
21        (4) the ultimate decision as to whether or not to
22    prescribe or dispense a controlled substance remains with
23    the prescriber or dispenser.
24    The Prescription Monitoring Program shall send to
25registered designees information regarding the inquiry system,
26including instructions on how to log onto the system.



10000SB2952sam004- 14 -LRB100 16820 RLC 39676 a

1    (r) The Prescription Monitoring Program shall maintain an
2Internet website in conjunction with its prescriber and
3dispenser inquiry system. This website shall include, at a
4minimum, the following information:
5        (1) current clinical guidelines developed by health
6    care professional organizations on the prescribing of
7    opioids or other controlled substances as determined by the
8    Advisory Committee;
9        (2) accredited continuing education programs related
10    to prescribing of controlled substances;
11        (3) programs or information developed by health care
12    professionals that may be used to assess patients or help
13    ensure compliance with prescriptions;
14        (4) updates from the Food and Drug Administration, the
15    Centers for Disease Control and Prevention, and other
16    public and private organizations which are relevant to
17    prescribing;
18        (5) relevant medical studies related to prescribing;
19        (6) other information regarding the prescription of
20    controlled substances; and
21        (7) information regarding prescription drug disposal
22    events, including take-back programs or other disposal
23    options or events.
24    The content of the Internet website shall be periodically
25reviewed by the Prescription Monitoring Program Advisory
26Committee as set forth in Section 320 and updated in accordance



10000SB2952sam004- 15 -LRB100 16820 RLC 39676 a

1with the recommendation of the advisory committee.
2    (s) The Prescription Monitoring Program shall regularly
3send electronic updates to the registered users of the Program.
4The Prescription Monitoring Program Advisory Committee shall
5review any communications sent to registered users and also
6make recommendations for communications as set forth in Section
7320. These updates shall include the following information:
8        (1) opportunities for accredited continuing education
9    programs related to prescribing of controlled substances;
10        (2) current clinical guidelines developed by health
11    care professional organizations on the prescribing of
12    opioids or other drugs as determined by the Advisory
13    Committee;
14        (3) programs or information developed by health care
15    professionals that may be used to assess patients or help
16    ensure compliance with prescriptions;
17        (4) updates from the Food and Drug Administration, the
18    Centers for Disease Control and Prevention, and other
19    public and private organizations which are relevant to
20    prescribing;
21        (5) relevant medical studies related to prescribing;
22        (6) other information regarding prescribing of
23    controlled substances;
24        (7) information regarding prescription drug disposal
25    events, including take-back programs or other disposal
26    options or events; and



10000SB2952sam004- 16 -LRB100 16820 RLC 39676 a

1        (8) reminders that the Prescription Monitoring Program
2    is a useful clinical tool.
3(Source: P.A. 99-480, eff. 9-9-15; 100-125, eff. 1-1-18.)
4    (720 ILCS 570/320)
5    Sec. 320. Advisory committee.
6    (a) There is created a Prescription Monitoring Program
7Advisory Committee to assist the Department of Human Services
8in implementing the Prescription Monitoring Program created by
9this Article and to advise the Department on the professional
10performance of prescribers and dispensers and other matters
11germane to the advisory committee's field of competence.
12    (b) The Prescription Monitoring Program Advisory Committee
13shall consist of 12 members appointed by the Clinical Director
14of the Prescription Monitoring Program The Clinical Director of
15the Prescription Monitoring Program shall appoint members to
16serve on the advisory committee. The advisory committee shall
17be composed of prescribers and dispensers licensed to practice
18medicine in his or her respective profession as follows: 4
19physicians licensed to practice medicine in all its branches;
20one advanced practice registered nurse; one physician
21assistant; one optometrist or ophthalmologist; one dentist;
22one podiatric physician; and 3 pharmacists. The Advisory
23Committee members serving on the effective date of this
24amendatory Act of the 100th General Assembly shall continue to
25serve until January 1, 2019. Prescriber and dispenser



10000SB2952sam004- 17 -LRB100 16820 RLC 39676 a

1nominations for membership on the Committee shall be submitted
2by their respective professional associations. If there are
3more nominees than membership positions for a prescriber or
4dispenser category, as provided in this subsection (b), the
5Clinical Director of the Prescription Monitoring Program shall
6appoint a member or members for each profession as provided in
7this subsection (b), from the nominations to serve on the
8advisory committee. At the first meeting of the Committee in
92019 members shall draw lots for initial terms and 4 members
10shall serve 3 years, 4 members shall serve 2 years, and 4
11members shall serve one year. Thereafter, members shall serve 3
12year terms. Members may serve more than one term but no more
13than 3 terms. The Clinical Director of the Prescription
14Monitoring Program may appoint a representative of an
15organization representing a profession required to be
16appointed. The Clinical Director of the Prescription
17Monitoring Program shall serve as the Secretary chair of the
19    (c) The advisory committee may appoint a chairperson and
20its other officers as it deems appropriate.
21    (d) The members of the advisory committee shall receive no
22compensation for their services as members of the advisory
23committee, unless appropriated by the General Assembly, but may
24be reimbursed for their actual expenses incurred in serving on
25the advisory committee.
26    (e) The advisory committee shall:



10000SB2952sam004- 18 -LRB100 16820 RLC 39676 a

1        (1) provide a uniform approach to reviewing this Act in
2    order to determine whether changes should be recommended to
3    the General Assembly;
4        (2) review current drug schedules in order to manage
5    changes to the administrative rules pertaining to the
6    utilization of this Act;
7        (3) review the following: current clinical guidelines
8    developed by health care professional organizations on the
9    prescribing of opioids or other controlled substances;
10    accredited continuing education programs related to
11    prescribing and dispensing; programs or information
12    developed by health care professional organizations that
13    may be used to assess patients or help ensure compliance
14    with prescriptions; updates from the Food and Drug
15    Administration, the Centers for Disease Control and
16    Prevention, and other public and private organizations
17    which are relevant to prescribing and dispensing; relevant
18    medical studies; and other publications which involve the
19    prescription of controlled substances;
20        (4) make recommendations for inclusion of these
21    materials or other studies which may be effective resources
22    for prescribers and dispensers on the Internet website of
23    the inquiry system established under Section 318;
24        (5) semi-annually on at least a quarterly basis, review
25    the content of the Internet website of the inquiry system
26    established pursuant to Section 318 to ensure this Internet



10000SB2952sam004- 19 -LRB100 16820 RLC 39676 a

1    website has the most current available information;
2        (6) semi-annually on at least a quarterly basis, review
3    opportunities for federal grants and other forms of funding
4    to support projects which will increase the number of pilot
5    programs which integrate the inquiry system with
6    electronic health records; and
7        (7) semi-annually on at least a quarterly basis, review
8    communication to be sent to all registered users of the
9    inquiry system established pursuant to Section 318,
10    including recommendations for relevant accredited
11    continuing education and information regarding prescribing
12    and dispensing.
13    (f) The Advisory Committee shall select from its members 11
14members of the Peer Review Committee composed of: The Clinical
15Director of the Prescription Monitoring Program shall select 5
16members, 3 physicians and 2 pharmacists, of the Prescription
17Monitoring Program Advisory Committee to serve as members of
18the peer review subcommittee.
19        (1) 3 physicians;
20        (2) 3 pharmacists;
21        (3) one dentist;
22        (4) one advanced practice registered nurse;
23        (4.5) one veterinarian;
24        (5) one physician assistant; and
25        (6) one optometrist or ophthalmologist.
26    The purpose of the Peer Review Committee peer review



10000SB2952sam004- 20 -LRB100 16820 RLC 39676 a

1subcommittee is to advise the Program on matters germane to the
2advisory committee's field of competence, establish a formal
3peer review of professional performance of prescribers and
4dispensers, and develop communications to transmit to
5prescribers and dispensers. The deliberations, information,
6and communications of the Peer Review Committee peer review
7subcommittee are privileged and confidential and shall not be
8disclosed in any manner except in accordance with current law.
9        (1) The Peer Review Committee peer review subcommittee
10    shall periodically review the data contained within the
11    prescription monitoring program to identify those
12    prescribers or dispensers who may be prescribing or
13    dispensing outside the currently accepted standard and
14    practice standards in the course of their profession
15    professional practice. The Peer Review Committee member,
16    whose profession is the same as the prescriber or dispenser
17    being reviewed, shall prepare a preliminary report and
18    recommendation for any non-action or action. The
19    Prescription Monitoring Program Clinical Director and
20    staff shall provide the necessary assistance and data as
21    required.
22        (2) The Peer Review Committee peer review subcommittee
23    may identify prescribers or dispensers who may be
24    prescribing outside the currently accepted medical
25    standards in the course of their professional practice and
26    send the identified prescriber or dispenser a request for



10000SB2952sam004- 21 -LRB100 16820 RLC 39676 a

1    information regarding their prescribing or dispensing
2    practices. This request for information shall be sent via
3    certified mail, return receipt requested. A prescriber or
4    dispenser shall have 30 days to respond to the request for
5    information.
6        (3) The Peer Review Committee peer review subcommittee
7    shall refer a prescriber or a dispenser to the Department
8    of Financial and Professional Regulation in the following
9    situations:
10            (i) if a prescriber or dispenser does not respond
11        to three successive requests for information;
12            (ii) in the opinion of a majority of members of the
13        Peer Review Committee peer review subcommittee, the
14        prescriber or dispenser does not have a satisfactory
15        explanation for the practices identified by the Peer
16        Review Committee peer review subcommittee in its
17        request for information; or
18            (iii) following communications with the Peer
19        Review Committee peer review subcommittee, the
20        prescriber or dispenser does not sufficiently rectify
21        the practices identified in the request for
22        information in the opinion of a majority of the members
23        of the Peer Review Committee peer review subcommittee.
24        (4) The Department of Financial and Professional
25    Regulation may initiate an investigation and discipline in
26    accordance with current laws and rules for any prescriber



10000SB2952sam004- 22 -LRB100 16820 RLC 39676 a

1    or dispenser referred by the peer review subcommittee.
2        (5) The Peer Review Committee peer review subcommittee
3    shall prepare an annual report starting on July 1, 2017.
4    This report shall contain the following information: the
5    number of times the Peer Review Committee peer review
6    subcommittee was convened; the number of prescribers or
7    dispensers who were reviewed by the Peer Review Committee
8    peer review committee; the number of requests for
9    information sent out by the Peer Review Committee peer
10    review subcommittee; and the number of prescribers or
11    dispensers referred to the Department of Financial and
12    Professional Regulation. The annual report shall be
13    delivered electronically to the Department and to the
14    General Assembly. The report to the General Assembly shall
15    be filed with the Clerk of the House of Representatives and
16    the Secretary of the Senate in electronic form only, in the
17    manner that the Clerk and the Secretary shall direct. The
18    report prepared by the Peer Review Committee peer review
19    subcommittee shall not identify any prescriber, dispenser,
20    or patient.
21(Source: P.A. 99-480, eff. 9-9-15; 100-513, eff. 1-1-18.)
22    Section 99. Effective date. This Act takes effect upon
23becoming law.".